The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

<p>Abstract</p> <p>Background</p> <p>Cerebral oedema is associated with significant neurological damage in patients with traumatic brain injury. Bradykinin is an inflammatory mediator that may contribute to cerebral oedema by increasing the permeability of the blood-bra...

Full description

Bibliographic Details
Main Authors: Rätsep Indrek, Ravi Ramalingam R, Pachl Jan, Murillo-Cabezas Francisco, Mantilla Jorge, Hartzenberg Bennie, Frost Chris, Fletcher Olivia, Druwé Patrick, Dewan Yashbir, Quintero Juan, Boeriu Cristian, Balica Laura, Asser Toomas, Andrews Peter, Shakur Haleema, Sampaio Cristina, Singh Manmohan, Svoboda Petr, Roberts Ian
Format: Article
Language:English
Published: BMC 2009-12-01
Series:Trials
Online Access:http://www.trialsjournal.com/content/10/1/109

Internet

http://www.trialsjournal.com/content/10/1/109

Similar Items